|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rate of HF associated with DPP4is was moderated when they were used in combination with SGLT2 inhibitors.
|
29549573 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While little is yet known about SGLT subtype 1, SGLT2 inhibitors have demonstrated to significantly reduce cardiovascular mortality and heart failure hospitalizations.
|
31277431 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the EMPA-REG OUTCOME trial revealed that empagliflozin, an inhibitor of the sodium-glucose cotransporter 2 (SGLT2), substantially reduced the risk of hospitalization for heart failure, death from cardiovascular causes, and all-cause mortality in patients with type 2 diabetes mellitus at high cardiovascular risk.
|
29016751 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with other glucose-lowering drugs, use of SGLT2 inhibitors was associated with decreased risk of cardiovascular mortality (HR 0·53 [95% CI 0·40-0·71]), major adverse cardiovascular events (0·78 [0·69-0·87]), and hospital events for heart failure (0·70 [0·61-0·81]; p<0·0001 for all).
|
28781064 |
2017 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on such evidence, the recent guidelines for the management of type 2 diabetes now suggest that SGLT-2 inhibitors should be preferred among oral agents in combination with metformin, in patients at increased cardiovascular risk, chronic kidney disease or heart failure.
|
31663470 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SGLT-2 inhibitors were significantly associated with lower rates of HF events (absolute RD, -1.1%; HR, 0.62 [95% CrI, 0.54 to 0.72]) and MI (absolute RD, -0.6%; HR, 0.86 [95% CrI, 0.77 to 0.97]) than were the control groups.
|
29677303 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with type II DM, SGLT-2 inhibitors appeared to reduce both all-cause and cardiovascular mortality, primarily due to reduction in the risk of heart failure.
|
27866027 |
2017 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, SGLT2 inhibitors were associated with lower risk of hospitalization because of heart failure compared to both sulfonylureas and DPP-4 inhibitors, as well as lower risk of lower extremity amputation compared to sulfonylureas.
|
30039524 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Trial sequential analysis provided firm evidence of a 20% reduction in major adverse cardiac events, all-cause mortality, and hospitalization for heart failure with SGLT2 inhibitors, but evidence remains inconclusive for cardiovascular mortality.
|
29353233 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the newest antidiabetic medications, sodium-glucose cotransporter 2 (SGLT2) inhibitors, have shown to significantly reduce CV mortality and heart failure (HF) hospitalizations.
|
30463454 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin).
|
28721687 |
2017 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Use of SGLT2 inhibitors in specific groups (e.g. those with nocturnal hypertension, diabetes, and high salt sensitivity) could help reduce the risk of heart failure and cardiovascular mortality.
|
30586745 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Traditional management of diabetes mellitus has focused on glycemic control, beginning with lifestyle changes, followed by metformin, and then other classes of antiglycemic agents.<sup>1</sup> Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular (CV) events, including CV death, myocardial infarction (MI) and heart failure, and slow progression of renal dysfunction, including prevention of end-stage kidney disease (ESKD).<sup>2-3</sup> Because initial clinical trials included mostly patients with baseline HbA1c >7%, current guidelines have recommended this class as add-on therapy for patients whose HbA1c is not at goal, typically ≥7%.<sup>1</sup> We hypothesized that there would be similar benefits on CV and renal endpoints regardless of baseline HbA1c, including those with HbA1c <7%.
|
31707795 |
2020 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cardiovascular outcome trials have documented a strong benefit of sodium glucose cotransporter-2 inhibitors (SGLT2i) on the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D) with or without established cardiovascular disease or prior history of HF.
|
31412874 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subgroup analysis from these major trials indicated a reduction in progression of nephropathy and HF readmission with SGLT2 inhibitors.
|
31627834 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
|
30817235 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The remarkable reduction in cardiovascular (CV) mortality (38%), major CV events (14%), hospitalization for heart failure (35%), and death from any cause (32%) observed over a period of 2.6 years in patients with T2D and high CV risk in the EMPA-REG OUTCOME trial involving the SGLT2 inhibitor empagliflozin (Empa) have raised the possibility that potential novel, more specific mechanisms of SGLT2 inhibition synergize with the known modest systemic improvements, such as glycemic, body weight, diuresis, and blood pressure control.
|
29322280 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It has recently been shown that the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors leads to a reduction in CV outcomes in patients with type 2 diabetes mellitus (T2DM), including mortality and heart failure hospitalization.
|
30618324 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ongoing clinical trials will uncover the potential benefit of SGLT2 inhibitors in patients with prevalent heart failure with or without diabetes mellitus.
|
31494110 |
2020 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
|
31176543 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, SGLT2 inhibitors lower risk of congestive heart failure, a major cardiovascular complication in DKD.
|
30665953 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the EMPA-REG OUTCOME trial, SGLT2 inhibition with empagliflozin reduced the primary outcome of major adverse cardiovascular events (MACE), while also reducing mortality, hospitalization for heart failure, and progression of diabetic kidney disease.
|
29735306 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DAPA-HF will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy, in a broad spectrum of patients with heart failure and reduced ejection fraction.
|
30895697 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SGLT2 inhibition reduced the risk of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (RR, 0.81; 95% CI, 0.70-0.94) and heart failure (RR, 0.61; 95% CI, 0.48-0.78), without a clear effect on all-cause mortality (HR, 0.86; 95% CI, 0.73-1.01).
|
30697905 |
2019 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, large placebo-controlled outcome trials have shown that sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduce the risk of CV disease (including CV death and hospitalization for heart failure) in people with type 2 diabetes who are at high risk of atherosclerotic disease, and these effects were largely independent of improvements in hyperglycaemia, BP and body weight.
|
30524708 |
2018 |